Trial
NCT03425331
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Dana-Farber Cancer Institute
Collaborators
Bristol-Myers Squibb
Condition
Non-small Cell Lung Cancer
Intervention
Ipilimumab
Why stopped
Slow accrual, competing studies, and lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-01-08